|Videos|April 18, 2022
Venetoclax in Combination with Daratumumab for Multiple Myeloma Treatment
Author(s)Shaji K. Kumar, MD, Jonathan L. Kaufman, MD
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.
Advertisement
Episodes in this series
Advertisement
Related to this article
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
4
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
5